🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. dehydroepiandrosterone

    Ultragenyx UK Limited

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    3 trials

  2. dehydroepiandrosterone

    Ultragenyx UK Limited

    Addison's Disease

    phase 3 small molecule completed

    1 trial

  3. delandistrogene moxeparvovec

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 gene therapy active

    7 trials

  4. denifanstat

    Sagimet Biosciences

    MASLD

    phase 3 small molecule terminated

    1 trial

  5. denosumab

    GlaxoSmithKline

    Osteoporosis, Postmenopausal

    phase 3 small molecule completed

    1 trial

  6. desiccated thyroid extract (DTE)+levothyroxine (L-T4)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intermediate-to-High Risk Differentiated Thyroid Cancer

    phase 3 small molecule active

    1 trial

  7. desipramine

    Ultragenyx UK Limited

    Pain

    phase 3 small molecule completed

    1 trial

  8. deucravacitinib, Placebo to match BMS 986165 tablet

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate-to-Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  9. deucravacitinib, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, Placebo to match deucravacitinib 2mg minitablets in sachet, oral use

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  10. deucravacitinib, Placebo to match deucravacitinib tablet

    Bristol-Myers Squibb Australia Pty Ltd

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  11. deucravacitinib, deucravacitinib, Deucravacitinib placebo 2mg film-coated tablets in sachet, oral use, deucravacitinib

    Bristol-Myers Squibb Australia Pty Ltd

    Juvenile Psoriatic Arthritis (JPsA)

    phase 3 small molecule active

    1 trial

  12. dexamethasone

    Ultragenyx UK Limited

    Bronchopulmonary Dysplasia

    phase 3 small molecule completed

    1 trial

  13. dichlorphenamide

    Ultragenyx UK Limited

    Paralysis, Hyperkalemic Periodic

    phase 3 small molecule completed

    1 trial

  14. different degrees of adjustment of the injection interval

    The First People's Hospital of Lianyungang

    Exudative Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  15. doxorubicin hydrochloride

    United Therapeutics Europe Ltd

    Stage III Bladder Cancer

    phase 3 small molecule completed

    1 trial

  16. doxorubicin hydrochloride

    Children's Hospital of Fudan University

    Adult Alveolar Soft-part Sarcoma

    phase 3 small molecule completed

    1 trial

  17. doxorubicin in combination with palifosfamide-tris

    Alaunos Therapeutics

    Soft Tissue Sarcoma

    phase 3 small molecule completed

    1 trial

  18. dupilumab

    Regeneron UK Limited

    Moderate to Severe Atopic Hand and Foot Dermatitis

    phase 3 small molecule completed

    1 trial

  19. dutasteride 0.5mg once daily for 4 years

    GlaxoSmithKline

    Prostatic Hyperplasia

    phase 3 small molecule completed

    1 trial

  20. dydrogesterone

    Hospital Authority, Hong Kong

    Preterm Delivery

    phase 3 small molecule completed

    1 trial

  21. eRapa (encapsulated rapamycin)

    Biodexa Pharmaceuticals Plc

    Familial Adenomatous Polyposis (FAP)

    phase 3 small molecule active

    1 trial

  22. ecallantide

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    4 trials

  23. eptacog alfa (activated)

    Novo Nordisk A/S

    Acquired Bleeding Disorder

    phase 3 small molecule completed

    1 trial

  24. evorpacept, Herceptin 150 mg powder for concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/mL concentrate for solution for infusion, Normal Saline (Sodium Chloride)

    Wuhan Createrna Science and Technology Co., Ltd

    Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources